FDA Rejects Replimune Drug Again; Revolution Medicines Pancreatic Cancer Pill Advances

The FDA issued its second rejection of Replimune's cancer drug application, dealing a significant blow to the biotech. In the same regulatory cycle, Revolution Medicines' pancreatic cancer pill continued to advance in the oncology pipeline, offering a potential new treatment option for one of oncology's hardest-to-treat cancers.